We aimed to identify independent genetic determinants of circulating CETP (cholesteryl ester transfer protein) to assess causal effects of variation in CETP concentration on circulating lipid concentrations and cardiovascular disease risk.
Circ Genom Precis Med. 2018;11:e002034. DOI: 10.1161/CIRCGEN.117. 002034 May 2018 2 C ETP (cholesteryl ester transfer protein) facilitates the net flux of cholesteryl esters from high-density lipoproteins (HDLs) toward very low-density lipoproteins (LDLs), coupled to a net flux of triglycerides from very LDL to HDL. 1 As such, CETP contributes to an atherogenic lipoprotein profile (ie, high LDL cholesterol [LDL-C]/HDL cholesterol [HDL-C] ratio), as has been extensively studied in both humans and in mice transgenic for human CETP. 2, 3 Therefore, inhibition of CETP has long been regarded a promising therapeutic strategy to attenuate dyslipidemia and ultimately prevent the development of cardiovascular disease (CVD).
Of the 4 clinical trials that have studied the effects of pharmacological CETP inhibition on CVD risk reduction, only the fourth and most recent REVEAL trial (Randomized Evaluation of the Effects of Anacetrapib through Lipid Modification) with anacetrapib did meet its primary end point, that is, a reduction in major coronary events. 4 Contrary to expectations, the clinical trials with the CETP inhibitors torcetrapib, dalcetrapib, and evacetrapib were terminated: torcetrapib had off-target effects on blood pressure and caused an increase in cardiovascular events, 5 and both dalcetrapib and evacetrapib lacked efficacy in reducing cardiovascular events on top of statin therapy. 6, 7 All of these CETP inhibitors caused a large increase in HDL-C and a low-to-moderate decrease in LDL-C. [5] [6] [7] [8] Although high HDL-C concentration is associated with a decreased risk of CVD in epidemiological studies, 9 Voight et al 10 showed in a Mendelian randomization study that genetically determined higher HDL-C concentrations do not decrease the risk of myocardial infarction, indicating that the association between HDL-C and CVD is not causal. This may be one of the explanations for the lack of efficacy of the 3 initial CETP inhibitors. Although the underlying reason for success of the fourth CETP inhibitor is not yet elucidated, anacetrapib showed the largest reduction in LDL-C concentration compared with the 3 initial CETP inhibitors, 4 which may possibly explain its beneficial effects on CVD risk reduction.
Recent evidence shows that serum CETP is largely derived from hepatic macrophages, 11 but the genetic basis of serum CETP concentration in the general population remains to be elucidated. A large genome-wide association study (GWAS) on circulating CETP has not been performed to date. With identification of the main genetic determinants of circulating CETP, the causal effects of variation in serum CETP concentration on circulating lipid concentrations and CVD risk can be assessed using Mendelian randomization. In the past, several Mendelian randomization studies with a comparable aim have been performed, [12] [13] [14] including a recent meta-Mendelian randomization analysis by Ference et al 15 with data from >100 000 participants. However, these studies used candidate single-nucleotide polymorphisms (SNPs) rather than GWAS-identified SNPs, which may be less-powerful genetic instruments for assessing the causal role of CETP concentration in CVD. 16, 17 With the present study, we aim to identify independent genetic variants that determine circulating CETP concentration, using a genome-wide rather than a candidate gene approach. In addition, we aim to use these variants as genetic instruments in Mendelian randomization to assess the causal effects of variation in CETP on serum lipids and coronary artery disease (CAD) risk, which may assist in understanding the effectiveness of pharmaceutical CETP inhibition. To this end, we performed a GWAS on serum CETP concentration, using a discovery cohort (n=4248) and a separate replication cohort (n=1458) from the NEO study (Netherlands Epidemiology of Obesity). Subsequently, we used the identified SNPs in Mendelian randomization analyses on serum lipid concentrations in the NEO study population and the Global Lipids Genetics Consortium (GLGC) 18 and on CAD using publicly available data from the CARDGIoGRAMplusC4D consortium.
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CLINICAL PERSPECTIVE
We have performed the first genome-wide association study on serum CETP (cholesteryl ester transfer protein) concentration using data of the NEO study (Netherlands Epidemiology of Obesity). With this effort, we identified 3 independent common genetic variants in the CETP gene, which explain as much as 16.4% of the total variation in serum CETP concentration. These CETP SNPs were subsequently used in Mendelian randomization analyses on high-density lipoprotein cholesterol concentration, low-density lipoprotein cholesterol concentration, and coronary artery disease (CAD). We showed that 1-µg/mL increase in serum CETP causally associates with a large decrease in highdensity lipoprotein cholesterol of −0.23 mmol/L, a moderate increase in low-density lipoprotein cholesterol concentration of 0.08 mmol/L, and a minor increase in the odds ratio for CAD risk of 1.08. Although high-density lipoprotein cholesterol is not a causal risk factor for CAD, it has been unequivocally demonstrated that low-density lipoprotein cholesterol lowering is proportionally associated with a lower CAD risk. Therefore, the results of our study are fully consistent with the notion that CETP concentration is causally associated with CAD through its effect on non-highdensity lipoprotein cholesterol. Because this effect is moderate, the effects of CETP concentration on CAD risk are of minor clinical relevance. Our data can, therefore, explain the paucity in succes of the recent trial with the CETP inhibitor anacetrapib as treatment for cardiovascular disease. 
METHODS
Study Design and Population
The NEO study is a population-based prospective cohort study of men and women aged between 45 and 65 years. From the greater area of Leiden, The Netherlands, all inhabitants with a self-reported body mass index (BMI) of ≥27 kg/m 2 were eligible to participate. In addition, inhabitants from one nearby municipality (Leiderdorp, The Netherlands) in the same age group were invited to participate regardless of their BMI, forming a reference population for BMI distribution. In total, 6671 participants were included from September 2008 until September 2012. Participants visited the NEO study center for extensive physical examination. Venous blood samples were obtained from the antecubital vein after a 10-hour overnight fast. Research nurses recorded current medication use by means of a medication inventory. Before the study visit, participants completed questionnaires at home with respect to demographic, lifestyle, and clinical information.
The NEO study was approved by the medical ethics committee of the Leiden University Medical Center, and all participants gave their written informed consent. Detailed information about the study design and data collection has been described elsewhere. 20 Methods used for genotyping and biochemical analyses are described in detail in the Data Supplement.
Because of consent issues, the individual data of NEO study participants will not be made available to other researchers for purposes of reproducing the results or replicating the procedure. However, a file including GWAS summary statistics can be requested via k.willems_van_dijk@lumc.nl.
Genome-Wide Association Study
We conducted the GWAS on the unstandardized serum CETP concentration for all autosomal chromosomes. We divided the total NEO study population based on the graphical area of recruitment into a discovery cohort (n=4248; greater area of Leiden, The Netherlands) and a replication cohort (n=1458; Leiderdorp, The Netherlands). This was considered to be valid because we recently showed, using data of the NEO study population, that serum CETP concentration was not associated with BMI or with other measures of body fat. 21 Additive (per allele) linear regression analyses were conducted separately for the discovery and replication cohorts in SNPTEST v2, adjusted for age, sex, and the first 4 PCs. To identify variants that were independently associated with serum CETP concentration, we used conditional and joint analyses to perform a stepwise selection procedure using the genome-wide complex trait analysis tool, version 1.24.4. 22 A conditioned P value <5×10 −8 was considered to be genomewide significant, and a conditioned P value <1×10 −6 was considered a suggestive signal. Independent SNPs with a conditioned P value <1×10 −6 in the discovery analysis were validated in the replication sample. SNPs with a P value <0.05 in the replication cohort were considered to be replicated. On identification of the lead SNPs, we determined whether the distribution of the coding alleles was similar in users and nonusers of lipid-lowering drugs. More detailed information on this method is described in the Data Supplement.
Because Taq1B (rs708272) 23 and −629C>A (rs1800775) 24 are the most studied variants in the CETP gene in literature, we specifically checked the GWAS results for their association with CETP concentration. In addition, we reported the linkage disequilibrium (NEO study) of the lead SNPs from the present GWAS with the 8 CETP SNPs that were used in a recent metaMendelian randomization study on coronary heart disease and serum lipids by Ference et al 15 (ie, rs3764261, rs1800775, rs1864163, rs9929488, rs9989419, rs12708967, rs289714, and rs5880). This allows comparison between our genetic instrument composed of SNPs identified form a GWAS on serum CETP concentration and their genetic instrument composed of candidate SNPs.
The explained variance in serum CETP concentration for the independent variants was estimated in the replication cohort. For each individual SNP, the explained variance was estimated as the partial R 2 from the linear regression model with the SNP as independent variable and serum CETP concentration as dependent variable. To estimate the total variance explained by all independent lead SNPs, a weighted genetic risk score (GRS) was calculated per individual. The GRS was constructed as the sum of the number of risk alleles on the lead SNPs weighted by their effect size on CETP concentration in the discovery cohort. The combined explained variance was the partial R 2 from the linear regression model, with the weighted GRS as independent variable and serum CETP concentration as dependent variable.
To quantify the genome-wide cumulative effects of independent variants influencing various phenotypes, genetic correlations of serum CETP concentration with serum lipid concentrations (ie, HDL-C, LDL-C, triglycerides, and total cholesterol) and BMI were calculated (Data Supplement).
Expression Quantitative Trait Loci Analysis
To investigate whether the identified lead SNPs could explain serum CETP concentration via transcriptional gene regulation, we checked whether these SNPs were expression quantitative trait loci (eQTLs) for CETP using data from the genotype-tissue expression project portal (V7) 25 and the Blood eQTL browser.
26
Mendelian Randomization
Based on the identified independent and replicated SNPs for serum CETP concentration in our study population, we conducted Mendelian randomization analyses on serum lipid concentrations in the NEO study population and on the risk of CAD based on publicly available summary statistics data from the CARDGIoGRAMplusC4D 1000 Genomes study. 19 A detailed description of the Mendelian randomization analyses on CAD risk using data from the CARDIoGRAMplusC4D consortium can be found in the Data Supplement. Effect estimates for CAD risk were reported as odds ratio with corresponding 95% confidence interval (CI). We used a publicly available tool 27 to conduct a power analysis for the Mendelian randomization analysis on CAD, which was based on the findings from the GWAS on serum CETP concentration, the explained variance of the SNPs used to compose the GRS, and the sample size of the CARDIoGRAMplusC4D 1000 Genomes study (60 801 cases and 123 504 controls).
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In the NEO study population, we calculated the individual weighted GRS based on the identified SNPs and determined the effect of 1-µg/mL increase in genetically determined CETP concentration on the concentrations of total cholesterol, HDL-C, triglycerides, LDL-C, total cholesterol/HDL-C ratio, LDL-C/HDL-C ratio, and ApoB (apolipoprotein B), using linear regression analysis adjusted for age and sex. β Coefficients and 95% CIs were reported. We reported total cholesterol, triglycerides, HDL-C, and LDL-C concentrations in mmol/L. To yield concentrations in mg/dL, cholesterol values should be multiplied by 38.67 and triglyceride values by 88.57. 28 In addition, for replication purposes, we extracted the independent lead SNPs from publicly available datasets of the GLGC. 18 We also extracted the Taq1B (rs708272) and −629C>A (rs1800775) polymorphisms from the CARDGIoGRAMplusC4D 1000 Genomes and GLGC datasets.
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RESULTS
Population Characteristics
Characteristics of the discovery and replication cohorts are summarized in Table 1 . Compared with the replication cohort, there were fewer women in the discovery cohort (50.6% versus 56.1%). Also, participants in the discovery cohort had a higher BMI (30.3 versus 25.6 kg/m 2 ) and more often used lipid-lowering drugs (17.5% versus 10.4%) than participants in the replication cohort. Serum CETP and lipid concentrations were comparable between both cohorts.
Genome-Wide Association Analysis
The −Log(P value) plot for the GWAS is shown in Figure 1 . The accompanying list of SNPs that reached genomewide significance (P<5×10 −8 ) is presented in Table I in the Data Supplement. After conditioning on the lead SNPs, 3 independent variants reached genome-wide significance (conditioned P<5×10 −8 ; Figure II in the Data Supplement), and 7 suggestive signals were identified (conditioned P<1×10 −6 ) in the discovery cohort ( Table 2 ). The 3 genome-wide significant variants were all mapped to the CETP gene. Notably, these independent variants were rs247616 (P=1.86×10 −64 ), rs12720922 (P=6.68×10 −13 ), and rs1968905 (P=1.66×10 −12 ), which had a per-allele increase (SE) in serum CETP of 0.32 (0.02; rs247616-C), 0.35 (0.02; rs12720922-A), and 0.12 (0.02) µg/mL (rs1968905-G). These 3 variants were all replicated in the replication analysis (P<0.05). In the NEO study, these variants together explained 16.4% of the serum CETP concentration. The distributions of the effect alleles of the 3 lead SNPs were similar for individuals taking lipid-lowering drugs and not taking lipid-lowering drugs (Table II in the Data Supplement). Several SNPs were suggestively associated with serum CETP concentration, including SNPs mapped to ADAMTS3, PPARG, and LPL.
The unconditioned per-allele effect size of the wellknown Taq1B (rs708272) and −629C>A (rs1800775) variants was 0.27 µg/mL for both SNPs (Table I in The linkage disequilibrium between the 3 lead SNPs and 8 SNPs that were used as genetic instruments for a CETP GRS in a recent meta-Mendelian randomization analysis on coronary heart disease and serum lipids 15 is shown in Figure III in the Data Supplement. The 2 strongest lead SNPs from the present GWAS, that is, rs247616 and rs12720922, were in high linkage disequilibrium with the 8 candidate SNPs of the GRS that were used in the study by Ference et al, 15 with the highest linkage disequilibrium between rs247616 and rs3764261 (0.996) and between rs12720922 and rs1864163 (0.646).
The genetic correlation of serum CETP concentration with serum lipid concentrations and BMI is reported in Table III Table 3 shows the eQTLs for the genetic variants rs247616, rs12720922, and rs1968905. The SNP that was the most strongly associated with serum CETP concentration in the GWAS, that is, rs247616, was identi- ). rs12720922 was an eQTL for NLRC5 but not for CETP. However, we found rs1864163, which is in moderate linkage disequilibrium with rs12720922 (LD=0.65), to be an eQTL for CETP in whole blood (P=8.5×10 −4 ; effect size A-allele, 3.33). The third lead SNP, that is, rs1968905, was not identified as an eQTL for CETP in the studied tissues, neither were any variants in strong linkage disequilibrium with this SNP. Figure 2 shows the results from the Mendelian randomization analyses on CAD risk and serum lipid and ApoB concentrations. We had a power of 0.90 to detect an odds ratio of 1.04 with conventional Mendelian randomization analyses (which makes use of a formal weighted GRS), when taking into account an α of 0.05, the explained variance of the SNPs that compose the GRS (ie, 16.4%), and the sample size of the CARDIoGRAMplusC4D 1000Genomes study. Per 1-µg/ mL increase in genetically determined serum CETP concentration, the odds ratio for CAD risk was 1.08 (95% CI, 0.94-1.23). For the lead SNPs separately, odds ratios were 1.11 (95% CI, 1.03-1.17) for rs247616, 1.08 (95% CI, 1.01-1.15) for rs12720922, and 0.89 (95% CI, 0.72-1.09) for rs1968905. For Taq1B and −629C>A, odds ratios for CAD risk were 1.02 (95% CI, 1.01-1.04) and 1.03 (95% CI, 1.01-1.05), respectively (Table IV in the Data Supplement).
eQTL Analysis of the Lead SNPs
Mendelian Randomization
A 1-µg/mL increase in genetically determined serum CETP concentration was associated with decreased total cholesterol concentration, that is, −0.14 (95% CI, −0.22 to −0.05) mmol/L, and HDL-C concentration, that is, −0.23 (95% CI, −0.26 to −0.20) mmol/L, whereas it was associated with increased serum LDL-C concentration, that is, 0.08 (95% CI, 0.00-0.16) mmol/L, and ApoB concentration, that is, 0.02 (95% CI, 0.00-0.03) g/L. Genetically determined serum CETP concentration was not associated with serum triglycerides concentration, that is, 0.02 (95% CI, −0.05 to 0.09) mmol/L. Table V in the Data Supplement shows the results from the Mendelian randomization analysis with data from GLGC. The results for total cholesterol, triglycerides, and LDL-C concentrations from GLGC were comparable with the results from the NEO study. Effect sizes for HDL-C were larger in GLGC than in the NEO study.
DISCUSSION
With this first large GWAS on serum CETP concentration, we identified and replicated 3 independent SNPs, all mapping to the CETP region. These 3 variants, notably rs12720922, rs247616, and rs1968905, explained Threshold for genome-wide significance is 5×10 −8 , based on the conditioned P value. ‡Threshold for the suggestive signals is 1×10 −6 . Threshold for replication is 0.05. CETP indicates cholesteryl ester transfer protein; Chr, chromosome; and SNP, single-nucleotide polymorphism.
*In the discovery cohort. †β Coefficient expressed as the difference in serum CETP concentration. ‡P value conditioned on the top lead SNPs using stepwise conditional analysis.
Circ Genom Precis Med. 16.4% of the total variation in serum CETP concentration. Effect sizes of all lead SNPs were large, with rs12720922-A having the largest effect on serum CETP: +0.35 µg/mL per additional risk allele. Also, we showed that genetically determined variation in circulating CETP associates with a stepwise substantial decrease in HDL-C concentration, a moderate increase in LDL-C and ApoB concentration, and a concordant 8% increase in CAD risk. We found 3 independent SNPs in the CETP region that largely explained CETP concentration. The association of the rs12720922 variant with circulating CETP, blood lipids, or risk of CAD has, to the best of our knowledge, never been described before. In the eQTL studies that we considered, 25,26 rs12720922 was not reported as an eQTL for CETP. However, rs1864163, which is in moderate linkage disequilibrium with rs12720922 (LD=0.65), was found to be an eQTL for CETP in whole blood, 26 although not in the liver. 25 Despite the absence of a direct association between rs12720922 and CETP mRNA levels, it is not ruled out that rs12720922 affects CETP levels via transcriptional regulation. Possibly, we were not able to identify eQTLs of rs12720922 for CETP because of the low sample size of eQTL studies in liver tissue and the dilution that is introduced by considering whole liver expression because CETP is specifically expressed by hepatic macrophages (ie, Kupffer cells).
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The second independent lead SNP, rs247616, is located in the promotor region of the CETP gene. 29 This SNP has also not been associated with serum CETP concentration before, but it has previously been shown that the minor allele of this variant (rs247616-T) is associated with decreased CETP mRNA expression in human liver and increased HDL-C concentrations, [29] [30] [31] [32] which is in line with our findings.
The third identified variant, rs1968905, was reported by 1 study to associate with HDL-C concentration specifically in Africans but has not been linked to serum CETP concentration previously. 33 Of note, rs1968905 is in strong linkage disequilibrium (LD=0.89) with rs1801706 (ie, G84A), which has been reported as a risk factor for CAD in South Indians. 34 Interestingly, rs1801706 is located in the 3′ untranslated region of the CETP gene, suggesting involvement in post-transcriptional regulation. 35 In addition to these lead SNPs, we found a suggestive signal (ie, rs117427818) that could be a potential fourth hit in the CETP gene. Its statistical significance was, however, largely reduced on conditional analyses. Indeed, this SNP is in linkage disequilibrium with (one of) the lead SNPs and not completely independently associated with serum CETP concentration (highest linkage disequilibrium with rs12720922; LD=0. 20) .
To obtain insight in the role of LDL-C and HDL-C in the causal association between serum CETP and CAD risk, we performed Mendelian randomization analyses on serum lipid concentrations. A higher CETP GRS was associated with a large decrease in HDL-C concentration and a moderate increase in LDL-C concentration. The strong association of genetically determined serum CETP concentration with HDL-C concentration is probably partially explained by a shared genetic background of these 2 phenotypes because as the genetic correlation between serum CETP concentration and HDL-C concentration was relatively high, which indicates pleiotropy. It should be noted, however, that HDL-C has been observationally, but not causally, associated with CVD risk. 10 Thus, although a genetically determined increase in serum CETP is causally associated with a decrease in HDL-C concentration, this likely does not explain the association between serum CETP and CAD risk. On the contrary, a causal, proportional, log-linear association between LDL-C concentration and CAD risk has been firmly established. 36 In a previously performed Mende- lian randomization study using an LDL-C GRS, it was shown that the odds ratio for CAD risk was 1.68 (1.51-1.87) per 1-SD increase in LDL-C (ie, 0.98 mmol/L). 37 To compare, we showed that per 1-µg/mL increase in serum CETP, LDL-C concentration increased with 0.08 mmol/L, and the odds ratio for CAD risk was 1.08. Thus, expressed per 0.98 mmol/L increase in LDL-C concentration, we observed 1.98× increase in CAD risk using the CETP GRS, which is comparable with the effect estimate found with the LDL-C GRS. 37 Taken together, our study suggests that the causal association between CETP concentration and CAD risk may be explained by effects on LDL-C concentration. Interestingly, a recent large meta-Mendelian randomization analysis by Ference et al 15 indicated that ApoB concentration is an even more important causal link between CETP and CAD risk than LDL-C concentration. This implies that an increase in the absolute number of very LDL, intermediate density cholesterol, and LDL (ie, non-HDL) particles, as reflected by ApoB concentration, because of increased circulating CETP may explain the association with CAD risk, rather than the amount of cholesterol in LDL particles.
Our findings are in line with this recent meta-Mendelian randomization analysis, including >100 000 participants who showed comparable effects for a CETP GRS on CAD risk, LDL-C, and ApoB concentration. 15 In that meta-analysis, a CETP GRS was composed of 8 candidate SNPs selected from the CETP gene with a forward conditional regression analysis on HDL-C concentration. In the present study, we identified 3 different CETP SNPs that independently determine circulating CETP concentration by using a hypothesis-free approach (ie, GWAS). These GWAS-identified SNPs are, therefore, direct genetic instruments to study the causal effects of CETP in Mendelian randomization. Although none of the lead SNPs that we identified with GWAS were included in the GRS composed by Ference et al, 15 we observed that the 2 strongest lead SNPs from our GWAS were in high-(rs247616)-to-moderate (rs12720922) linkage disequilibrium with the 8 candidate SNPs of that GRS. This indicates that the GRS composed of candidate CETP SNPs is a reliable genetic instrument to study the causal effects of CETP, and our results, therefore, extend this recent meta-Mendelian randomization analysis. 15 Although we showed a causal association between CETP concentration and CAD risk, the 3 initial CETP inhibitors did not reduce the risk of cardiovascular events when given in addition to statin treatment. In fact, clinical trials with those CETP inhibitors were even terminated because of off-target effects (torcetrapib) or a lack of efficacy (dalcetrapib and evacetrapib). [5] [6] [7] Dalcetrapib had minimal effects in LDL-C concentration possibly explaining its futility. 6 Evacetrapib did significantly reduce LDL-C concentration but did not evoke a concordant decrease in ApoB, 38 indicating unfavorable LDL particle remodeling rather than removal from the circulation. 36, 39 This explanation for the failure of the evacetrapib trial is in line with a recent meta-Mendelian randomization study by Ference et al. 15 Data from that study indicate that the success of CETP inhibitors when prescribed on top of statin treatment is dependent on their capability to reduce the absolute number of non-HDL particles as reflected by a reduction in ApoB concentration. A reduction in the LDL-C concentration through CETP inhibition may thus only be beneficial when a concordant reduction in ApoB concentration is achieved. 15 Indeed, anacetrapib did show a concordant reduction in non-HDL and ApoB concentration of −18%, which was accompanied by a reduced rate ratio for major coronary events of 0.91 (95% CI, 0.85-0.97). 4 Our study may have had insufficient statistical power to identify additional variants with small effects on serum CETP concentration or with low allele frequencies. Because we did not replicate our GWAS findings in additional heterogeneous populations, caution should be taken when extrapolating the results to other populations. Also, despite the similar associations between the lead SNPs and LDL-C concentrations in GLGC and the NEO study, effect sizes for HDL-C concentrations were higher in GLGC. A possible explanation might involve differences in the composition of the study populations because GLGC is a meta-analysis of a wide variety of cohorts.
In conclusion, with a GWAS, we identified and replicated 3 independent SNPs mapping to the CETP gene that together explained 16.4% of the total variation in serum CETP concentration, which shows that serum CETP concentration is strongly genetically determined. Using Mendelian randomization, we showed that 1-µg/ mL increase in serum CETP causally associates with a large decrease in HDL-C cholesterol of −0.23 mmol/L, moderate increases in LDL-C concentration of 0.08 mmol/L and ApoB concentration of 0.02 g/L, and an odds ratio of 1.08 for CAD risk. Although HDL-C is not a causal risk factor for CAD, it has been unequivocally demonstrated that LDL-C lowering is proportionally associated with a lower CAD risk. Therefore, the results of our study are fully consistent with the notion that CETP concentration is causally associated with CAD through LDL-C.
